Motiva SmoothSilk Breast Implants Now Available on Boston’s South Shore

Christine Hamori, MD, FACS and Christine DiEdwardo, MD, FACS are pleased to announce that their Duxbury plastic surgery practice is among the first to offer Motiva Implants® approved by the FDA late last year for breast augmentation surgery and breast implant revision surgery.

Only Motiva Implants feature the unique SmoothSilk® 4-micron surface, shown to promote low inflammation and low bacterial attachment. The Motiva implants have an unmatched safety profile and exceptional patient satisfaction results.

“Motiva Implants, with their unique gel matrix allows creating the best breast shape, said Dr. Hamori. “The Ergonomix has quickly become my go-to for thin patients who prefer a tear drop shaped breast implant.”

Motiva® offers 2 different implant styles, each available in 3 projection levels:
Mini, Demi, and Full.

Motiva SmoothSilk® Round

This implant combines the SmoothSilk® Surface with ProgressiveGel PLUS®, creating increased upper pole fullness and softness. The shape keeps its round, full form regardless of whether you’re standing up or lying down.

Motiva SmoothSilk Ergonomix®

This implant combines the SmoothSilk® Surface with ProgressiveGel ULTIMA® to realistically mimic the look, feel and movement of a natural breast. Ergonomix® implants are unique to the implant market, as they can adapt shape as your body changes positions, showcasing a round shape when lying down and a teardrop shape when standing up. This breakthrough implant is designed to be inserted through a small incision6 to minimize scarring.

In the nearly four million devices in market worldwide, Motiva Implants have had no reported primary device-related proliferativediseases such as (BIA-ALCL, BIA-SCC and B-cell lymphomas). For more information and citations visit motivausa.com.

To learn if you are a candidate for a breast augmentation or breast implant revision surgery using Motiva Implants, please contact our office to schedule a surgical consult with Dr. Hamori or Dr. DiEdwardo.

Christine Hamori Cosmetic Surgery + Skin Spa
113 Tremont Street, Duxbury, Massachusetts, 02332
Call us: 781-934-2200
Serving Boston's South Shore, Cape Cod and Nantucket

Notice: Allergan Withdraws Textured Breast Implants

Allergan has announced today that it has voluntarily withdrawn BIOCELL Textured Breast Implants and Tissue Expanders from the worldwide market.

Effective immediately, healthcare providers will no longer implant new BIOCELL® textured breast implants and tissue expanders and unused products should be returned to Allergan. The withdrawal followed a request of the US FDA, which was based on new available data.

Allergen emphasized that there is still no recommendation to remove or replace textured breast implants from patients without symptoms.

I have implanted only a handful of this type of implant over the past 20 years. My office will individually notify those patients.

This global recall does not affect Allergan’s NATRELLE® smooth or MICROCELL® breast implants and tissue expanders.

See Allergan press release for more information.

Christine Hamori Cosmetic Surgery + Skin Spa
113 Tremont Street, Duxbury, Massachusetts, 02332
Call us: 781-934-2200
Serving Boston's South Shore, Cape Cod and Nantucket

Important Information about Breast Implants and BIA-ALCL

By Christine A. Hamori, MD

Recent media coverage of an FDA update regarding BIA-ALCL (Breast Implant Associated Anaplastic Large Cell Lymphoma) is causing a lot of concern among breast implant patients. First of all, patients should know that BIA-ALCL is not new, and that this is a very rare disease. Also, it is only associated with textured implants. During every breast augmentation consult I do with every potential patient, we go over this information. In fact, rarely do my patients and I choose a textured implant.

My colleague Dr. William Adams has published this informative update with a video from the Plastic Surgery Channel: An Update to Breast Implant-Associated ALCL.

The video is below for your viewing.



The bottom line, as spelled out in this report, is:

"Breast Implant-Associated ALCL is not new and there is excellent research and progress in reducing its occurrence and improving the treatment should it occur.  Here’s what patients should know:

• It is a rare disease that appears to be associated with TEXTURED breast implants
• If you notice significant swelling or changes in breast shape and size, call your plastic surgeon
• If diagnosed and treated properly, it is curable
• Patients desiring breast implants should know the difference between textured and smooth implants and discuss the best option for them with their surgeon."

I also recommend this in-depth post by another colleague, Dr. Karen Horton: ALCL and Breast Implants? The Rare Incidence of Anaplastic Large Cell Lymphoma

The FDA information page on ALCL has these recommendations for patients:

Educate yourself about breast implants before agreeing to surgery. Breast implants approved in the U.S. can be filled with either saline or with silicone gel. They come in different sizes and shapes and have either smooth or textured surfaces (shells). Additional information is available on FDA's Breast Implants website.

Although it is rare, BIA-ALCL appears to develop more frequently in women with textured implants than in women with smooth-surfaced implants. Before getting breast implants, make sure to talk to your health care provider about the benefits and risks of textured-surface vs. smooth-surfaced implants.

If you have breast implants, there is no need to change your routine medical care and follow-up. BIA-ALCL is rare. Although not specific to BIA-ALCL, you should follow standard medical recommendations including:

• Follow your doctor's instructions on how to monitor your breast implants. If you notice any changes, contact your health care provider promptly to schedule an appointment. Get routine mammography screening and ask for a technologist specifically trained in performing mammograms on patients with breast implants.
• If you have silicone gel-filled breast implants, get periodic magnetic resonance imaging (MRI) to detect ruptures as recommended by your health care provider. The FDA-approved product labeling for silicone gel-filled breast implants states that the first MRI should occur three years after implant surgery and every two years thereafter.

Additional Recommended Resources on BIA-ALCL:

• American Society of Plastic Surgeons page
• FDA information page

Please explore these excellent resources, and, as always, if you have additional questions or note any swelling, please contact my office at 781-934-2200 to schedule a consultation.

Christine Hamori Cosmetic Surgery + Skin Spa
113 Tremont Street, Duxbury, Massachusetts, 02332
Call us: 781-934-2200
Serving Boston's South Shore, Cape Cod and Nantucket

Breast Lift Surgery Becoming More Popular — Cosmetic Trends

The American Society of Plastic Surgeons (ASPS) has released this video describing the surge in popularity of breast lifts.

Here is the video: Breast Lift Surgery up 70% Since 2000


Breast lift surgery (or mastopexy) is often done in conjunction with breast implants, but certainly not always. Each women's needs and desires are different. When you come in for an initial consultation, we will discuss your goals and review the options, which often gets into the distinct benefits between silicone and saline implants.

There are many great options available for women today. If you are unhappy with your breasts and think you may want to do something about it, I encourage you to at least come in for a no-pressure consultation.

To learn more about breast lifts, please explore information and educational resources on my website, please click on: breast lift and breast implant.

To schedule a breast lift consultation, please contact the office at 781-934-2200.

Christine Hamori Cosmetic Surgery + Skin Spa
113 Tremont Street, Duxbury, Massachusetts, 02332
Tel. 781-934-2200
Serving Boston's South Shore, Cape Cod and Nantucket

Recommended: FDA Guidance on Breast Implants

This summer the FDA updated its information resources related to breast implants. As the FDA writes, "Breast implants are medical devices that are implanted under the breast tissue or under the chest muscle to increase breast size (augmentation) or to rebuild breast tissue after mastectomy or other damage to the breast (reconstruction). They are also used in revision surgeries, which correct or improve the result of an original surgery."

The FDA pages on breast implants are a good resource for unbiased information and worth review for anyone who is considering breast implants or has had implant surgery. The information is designed to support, not replace, the relationship that exists between patient and physician. Check it out at: FDA Breast Implants.

Silicone Implants Standing Up to FDA Post-Approval Studies So Far

The FDA held hearings yesterday and the day before as part of the long-term post-approval process for silicone gel-filled breast implants, which were approved to return to the market in 2006. The hearings are part of an information gathering effort to evaluate strengths and weakness of the implants and their long-term effectiveness. More will be forthcoming on this topic over time.

What these post-approval studies have shown so far, according to a news bulletin I received this week from the American Society of Plastic Surgeons is that, quoting ASPS President Phil Haeck, MD:

"At roughly the midpoint of the studies, we know that the pre-market data supporting safety and efficacy have been largely verified."

Also of interest from the same ASPS bulletin:

"Numerous studies have demonstrated a high level of patient satisfaction with silicone breast implants and no established relationship between silicone breast implants and connective tissue disorders, one of the primary reasons these studies were implemented."

On June 22, the FDA issued an updated white paper on the safety of silicone gel-filled breast implants, stating that "silicone gel-filled breast implants have a reasonable assurance of safety and effectiveness when used as labeled." The Agency also noted that women who receive silicone gel-filled breast implants for reconstructive or cosmetic purposes will need to monitor the devices over their lifetime.

A report on the hearings will be published in the October/November PSN and PSNExtra.org.

FDA Issues Safety Signal on ALCL and Breast Implants

Healthcare Alert: I thought it best to get this information out right away. Both the American Society of Plastic Surgeons and the American Society for Aesthetic Plastic Surgery have advised their members regarding the FDA Safety Signal about a possible association between breast implants and anaplastic large cell lymphoma (ALCL). Although ALCL is extremely rare, the FDA believes that women with breast implants may have a very small but increased risk of developing the condition.

It is important to note as the ASAPS does in today's member advisory...

"This condition is incredibly rare — in the past 25 years only 34 cases have been reported worldwide among an estimated 10 million+ implanted devices. In addition, as opposed to the systemic, nodal pattern of ALCL, in published reports ALCL seen in the presence of breast implants has demonstrated an indolent course: both with women experiencing aggressive systemic therapy as well as those treated with simple explantation and capsulectomy - the condition was resolved."

The FDA is recommending that health care professionals and women pay close attention to breast implants and do the following:

• Health care professionals are requested to report all confirmed cases of ALCL in women with breast implants to Medwatch, the FDA’s safety information and adverse event reporting program. Report online or by calling 800-332-1088.
• Health care professionals should consider the possibility of ALCL if a patient has late onset, persistent fluid around the implant (peri-implant seroma). In cases of implant seroma, send fresh seroma fluid for pathology tests to rule out ALCL.
• There is no need for women with breast implants to change their routine medical care and follow-up. ALCL is very rare; it has occurred in only a very small number of the millions of women who have breast implants. Although not specific to ALCL, health care providers should follow standard medical recommendations.
• Women should monitor their breast implants and contact their doctor if they notice any changes.
• Women who are considering breast implant surgery should discuss the risks and benefits with their health care provider.

The FDA published its literature review in a document posted on FDA’s website site today titled “Anaplastic Large Cell Lymphoma (ALCL) in Women with Breast Implants: Preliminary FDA Findings and Analyses.”